Abstract
The induced expression of c-Myc in plasmacytomas in BALB/c mice is regularly associated with nonrandom chromosomal translocations that juxtapose the c-myc gene to one of the Ig loci on chromosome 12 (IgH), 6 (IgK), or 16 (IgL). The DCPC21 plasmacytoma belongs to a small group of plasmacytomas that are unusual in that they appear to be translocation-negative. In this paper, we show the absence of any c-myc-activating chromosomal translocation for the DCPC21 by using fluorescent in situ hybridization, chromosome painting, and spectral karyotyping. We find that DCPC21 harbors c-myc and IgH genes on extrachromosomal elements (EEs) from which c-myc is transcribed, as shown by c-myc mRNA tracks and extrachromosomal gene transfer experiments. The transcriptional activity of these EEs is supported further by the presence of the transcription-associated phosphorylation of histone H3 (H3P) on the EEs. Thus, our data suggest that in this plasmacytoma, c-Myc expression is achieved by an alternative mechanism. The expression of the c-Myc oncoprotein is initiated outside the chromosomal locations of the c-myc gene, i.e., from EEs, which can be considered functional genetic units. Our data also imply that other “translocation-negative” experimental and human tumors with fusion transcripts or oncogenic activation may indeed carry translocation(s), however, in an extrachromosomal form.
The activation of the c-myc gene is key to the development of all murine plasmacytomas (PCTs), resulting in deregulated levels of endogenous c-Myc protein expression (1–3). In the majority of pristane-induced mouse PCTs, the deregulation of c-myc transcription is achieved by chromosomal translocation that juxtaposes the c-myc/pvt-1 locus on chromosome 15 to one of the Ig loci: on chromosome 12 (IgH), 6 (IgK), or 16 (IgL) (2, 3).
In a few PCTs, classical G banding analysis could not identify any of the PCT-associated typical or variant translocations (3). Molecular and cytogenetic analysis of the translocation-negative PCTs revealed that the overexpression of the c-myc gene was achieved by different means. c-Myc deregulation resulted from either promoter/enhancer insertion brought about by retroviral insertion into the 5′ flanking region of c-myc (4), insertion of the Ig heavy chain enhancer (5), or complex genomic rearrangements (6, 7). Although less than 1% of the PCTs analyzed to date belong to the group of translocation-negative PCTs, they are of interest because they may reveal a new mechanism of plasmacytomagenesis. Consequently, the lack of cytogenetically identifiable translocations suggests alternate pathways by which c-Myc overexpression is achieved in this group of tumors.
To examine the mechanism(s) of c-Myc deregulation in translocation-negative PCTs, we focused our investigation on DCPC21, a PCT that had been induced by i.p. implantation of a plastic diffusion chamber into a BALB/c female mouse (6). Previous work by these authors had suggested that DCPC21 exhibited complex molecular rearrangements leading to the IgH–myc gene juxtaposition by the insertion of the myc- and pvt-1 loci-containing chromosome 15 segment into the IgH locus on chromosome 12 (7). The realization of such a complex rearrangement requires the occurrence of a paracentric inversion, a deletion/insertion, and multiple translocations both on chromosome and gene levels during the process of the IgH–myc illegitimate recombination (7).
Here we report that the results of classical and molecular cytogenetic analyses show that the DCPC21 PCT lacks any type of interchromosomal recombination that could cause the constitutive activation of the c-myc gene. However, chromosomal segments containing c-myc and IgH sequences are present—either alone or jointly—on extrachromosomal elements (EEs) in the DCPC21 PCT. We demonstrate that the deregulated expression of c-myc occurs on EEs, and this appears to be sufficient to sustain the malignant phenotype of the DCPC21 tumor.
Materials and Methods
Tumor Cells.
DCPC21 was induced in a female BALB/c mouse by i.p. implantation of a Millipore diffusion chamber (8).
Trypsin-Giemsa Banding.
Metaphase spreads were prepared without Colcemid treatment. Trypsin-Giemsa banding was performed as described previously (9) and adapted to mouse chromosomes. Chromosome identification followed the recommendations of the Committee on Standardized Genetic Nomenclature for Mice (10).
Molecular Cytogenetics.
Chromosomes were analyzed by FISH (fluorescent in situ hybridization) as published previously (11, 12). Analysis of slides was performed by using a Zeiss Axiophot microscope, a Power Macintosh 8100 computer, and a charge-coupled device camera (Photometrics); the analytical software used was iplabspectrum 3.1 (Signal Analytics, Fairfax, VA).
FISH Probes and Detection of Hybridization.
The following probes were used: c-myc (13), IgH (pJ11; ref. 14), and pvt-1 (15). The probes were labeled by random priming with either digoxigenin- or biotin-dUTP (Roche Diagnostics). The detection of hybridization signals with digoxigenin-labeled probes was carried out by using a fluorescein-conjugated polyclonal sheep anti-digoxigenin antibody (Roche Diagnostics). For the detection of hybridization signals obtained with biotinylated probes, we used a monoclonal anti-biotin antibody (Roche Diagnostics) followed by a Texas Red-conjugated goat anti-mouse-IgG secondary antibody (Southern Biotechnology Associates).
FISH-EEs (FISH on Purified Extrachromosomal DNA Molecules).
The total population of EEs was purified and examined by FISH as described (T.I.K., J. T. Paul, J. A. Wright, J. F. Mushinski, and S.M., http://www.biomednet.com/db/tto). EEs were hybridized with c-myc, IgH, and pvt-1. The specificity of these hybridizations was confirmed by the absence of hybridization signals with a negative control, cyclin C (ref. 11; T.I.K., et al., http://www.biomednet.com/db/tto) and hybridization signals obtained with a positive control, cot-1 DNA (not shown).
Chromosome Painting.
The chromosome paints used (Cedarlane Laboratories) were a FITC-conjugated mouse chromosome 15 and a biotinylated mouse chromosome 12-specific paint. Hybridization of chromosome paints, alone or in combination with FISH probes, was carried out as described in the general FISH protocol. Chromosome 12 hybridization signals were detected with a monoclonal anti-biotin antibody (Roche Diagnostics) at 0.5 ng per slide followed by a Texas Red-conjugated goat anti-mouse-IgG secondary antibody (Southern Biotechnology Associates) at 2.5 ng per slide. The hybridization signals of the FITC-labeled chromosome 15 paint were amplified by using a rabbit anti-FITC antibody (Cedarlane Laboratories), followed by a FITC-labeled goat anti-rabbit IgG secondary antibody (Sigma). Both antibodies were used at 1:40 dilution.
Spectral Karyotyping (SKY).
SKY was performed by using the ASI (Applied Spectral Imaging, Carlsbad, CA, and Migdal Ha’Emek, Israel) kit for mouse spectral karyotyping and the suppliers’ hybridization protocols. Analyses were carried out by using the Spectra Cube on a Zeiss Axiophot 2 microscope and the skyview 1.2 software on a PC (PII-350).
mRNA Track Studies.
mRNA tracks studies were carried out as described in ref. 16 on freshly isolated ascitic DCPC21 tumor cells. The cells were cytospun onto microscopic slides (105 cells per slide) and fixed in formaldehyde (1% in 1× PBS/50 mM MgCl2). The slides were washed in 2× SSC and dehydrated sequentially in 70%, 90%, and 100% ethanol. A denatured mouse c-myc probe, pMycEx2, a 460-bp PstI-fragment of myc exon 2 (gift from K. Huppi, National Institutes of Health, Bethesda, MD), was added in 50% formamide/2× SSC/50 mM phosphate buffer/10% dextran sulfate for overnight hybridization at 37°C in a humidified incubator. As expected, subsequent RNase treatment removed any hybridization signals, and hybridization to chromosomes or extrachromosomal material was achieved only after the slides had been treated with RNase and pepsin and denatured before the addition of FISH probes (see also ref. 17).
Fluorescent Immunohistochemistry.
Immunohistochemistry was performed as described (12). A monoclonal anti-c-Myc antibody, 3C7 (18), was used at 20 ng per slide. Visualization of this antibody was achieved with a Texas Red-conjugated secondary goat anti-mouse IgG antibody (Southern Biotechnology Associates) at 2.5 ng per slide. A sheep anti-CORE histone antibody (United States Biological) was used at 5 ng per slide and visualized with a FITC-conjugated donkey anti-sheep IgG antibody (Sigma) at 2.75 ng per slide. The anti-histone H3P antibody used is a histone H3-phophoserine mAb from Z. Darzynkiewicz (19). It was used at 4.0 ng per slide and visualized with a Texas Red-conjugated goat anti-mouse IgG antibody (Southern Biotechnology Associates) at 2.5 ng per slide.
Southern Analysis.
For Southern analyses, 10 μg of DNA from primary BALB/cRb6.15 spleen or DCPC21 tumor DNA was digested overnight with 40 units of either HindIII or SacI restriction endonucleases (Roche Diagnostics) and electrophoretically separated on a 0.8% agarose gel, blotted onto Hybond XL membrane (Amersham Pharmacia), and baked at 80°C for 2 hr. Hybridizations and washes were carried out according to standard procedures (20). The probes used were c-myc (13), pJ11 (14), pvt-1 (15, 21), and JQ2 (7).
Electroporations.
Spleen cells of BALB/cRb6.15 mice were harvested for extrachromosomal gene transfer studies as follows. Green fluorescent protein (GFP, pEGFP-N1; CLONTECH) was used as a tracer molecule for determination of gene transfer efficiencies. Lymphocytes isolated from one spleen were divided into three groups: electroporation of GFP plus c-myc/IgH-carrying EEs (2.5 μg), electroporation of GFP (2.5 μg), and “mock” electroporation. Electroporations were carried out in OPTI-MEM solution (Canadian Life Technologies, Burlington, Ontario, Canada) by using 1-ml Gene Pulser cuvettes (Bio-Rad) a Bio-Rad electroporator, model 1652076, and a Bio-Rad Capacitance Extender, model 1652087. The settings used were: 960 μF, 240 V. Subsequent to electroporation, the cells were washed in complete medium [RPMI 1640 with 10% FCS (Canadian Life Technologies)] and 2 mM l-glutamine/5 units/ml penicillin/5 μg/ml streptomycin/50 μM 2-mercaptoethanol] and allowed to grow in complete medium in a humidified incubator at 37°C and in the presence of 5% CO2. Twenty-four hours after gene transfer, cells were cytospun onto microscope slides (105 cells per slide), and c-Myc protein expression was determined in splenic B cells that also expressed GFP. A FITC-conjugated anti-B220 antibody (PharMingen) was used to visualize splenic B cells on Cytospin preparations. Fluorescent immunohistochemistry of the electroporated cells was carried out as described previously (12).
Results
DCPC21 Is a Translocation-Negative PCT Harboring Extrachromosomal Elements.
Karyotyping of DCPC21 metaphase spreads by standard G banding revealed that chromosomes 15, 12, 6, and 16, regularly involved in mouse PCT-specific translocations, were not part of reciprocal translocation events (Fig. 1a). To confirm the results provided by G banding, DCPC21 metaphases were examined further by chromosome painting, FISH, and SKY (Fig. 1 b–e). Because the most frequent translocation (>90%) in pristane-induced mouse PCT transposes the c-myc-containing segment of chromosome 15 into the neighborhood of the IgH gene loci on chromosome 12 (3), chromosome painting was performed to ascertain whether chromosomes 12 and 15 are carriers of cryptic rearrangements. The painting with chromosome 15- and 12-specific probes revealed the presence of four copies of chromosome 15 (green) and chromosome 12 (red) in the majority of the DCPC21 plates analyzed. More importantly, neither chromosome 15- nor chromosome 12-derived genetic material was found to be translocated or inserted into any other chromosome of DCPC21 metaphases (Fig. 1 b and c).
When either chromosome 12 paint was combined with FISH by using a c-myc probe or chromosome 15 paint was used in combination with an IgH probe (pJ11), it was also evident that chromosomes 12 and 15 were not involved in reciprocal translocations (Fig. 1d and data not shown). However, EEs carrying either c-myc or IgH genes alone or c-myc and IgH genes jointly became apparent (Fig. 1d, arrow).
The possible involvement of the IgK- and IgL-carrying chromosomes 6 and 16 in Ig/myc translocation was analyzed by SKY (Fig. 1e). SKY corroborated the data obtained by standard cytogenetics, painting, and FISH, namely, that DCPC21 does not carry any PCT-associated c-myc-activating chromosomal translocation.
In addition, SKY revealed the nature and structure of the chromosomal aberrations detected by G banding. Noteworthy, SKY showed that the duplicated D2 band on one of the chromosomes 15 (Fig. 1a, arrow) contained only chromosome 15-derived genetic material (Fig. 1e), excluding the likelihood of an interchromosomal rearrangement involving chromosome 15. The additional band on chromosome 9 was identified as derived from chromosome 16, whereas one copy of chromosome 16 was centromerically fused with one chromosome 19. A “hidden” chromosomal aberration, undetected by classical G banding, was the insertion of chromosome 3-derived material into one chromosome 2. Because the aberrations involving chromosomes 9 and 2, as well as the fusion of chromosomes 16 and 19, were not consistently seen in all metaphases, they are likely chromosomal aberrations acquired during tumor progression, rather than during tumor initiation.
Classical cytogenetics, chromosome painting, FISH, and SKY establish that the DCPC21 PCT lacks any chromosomal aberration that reasonably could be involved in the constitutive activation of the c-myc gene. However, the presence of IgH and c-myc sequences on EEs suggests that these genetic entities may be responsible for the deregulation of c-Myc in this tumor.
Southern Blot Analysis Shows Rearrangements Within the IgH Locus and in the 5′ Flanking Region of c-myc.
Southern blot analysis was performed with normal mouse spleen DNA and DCPC21 tumor DNA. The c-myc gene, visualized by using a mouse exon 2-specific probe, showed no rearrangement(s) and exhibited identical hybridization patterns in HindIII and SacI digests of normal spleen and DCPC21 DNA (Fig. 2a). Similarly, pvt-1 showed no evidence of rearrangements (Fig. 2c). The stronger hybridization signals of c-myc and pvt-1 in DCPC21 DNA reflect both the duplication of the myc/pvt-1-containing 15D2 band of one chromosome 15 (Fig. 1a, arrow) and the additional copies of chromosome 15 (Fig. 1). In contrast to the germ-line bands observed with c-myc and pvt-1, rearrangements within the IgH sequences and in the 5′ flanking region of c-myc became apparent when using the IgH probe (pJ11) as well as a 5′ flanking probe of the c-myc gene (JQ2) (Fig. 2 b and d, respectively).
Because none of the bands that hybridized with pJ11 cohybridized with JQ2, it can be excluded that any of the additional bands represent a cryptic transposition of sequences detected by pJ11 and JQ2. Furthermore, a transposition of pvt-1 and c-myc within the chromosomal DNA of DCPC21 is unlikely, because, as shown in Fig. 2, these two genes were not involved in translocation and or rearrangement events detectable in genomic DNA. These results suggest that the rearranged genomic bands represent intrachromosomal rearrangements, possibly because of the excision of c-myc and IgH sequences from the relevant chromosomes rather than interchromosomal recombination.
c-myc and IgH Colocalize on EEs and Are Functional Genetic Units.
We consistently observed extrachromosomal c-myc and IgH hybridization signals in DCPC21 metaphases (Fig. 1). To analyze these EEs further, we performed FISH on the total population of EEs. Fig. 3 illustrates the findings for FISH-EEs hybridized with c-myc and IgH probes. In the majority of the cases, c-myc and IgH were found together on the large EEs [0.1–0.2 μm in diameter, as determined by electron microscopy (EM) measurements] (Fig. 3d). Notably, c-myc and IgH also were found alone on EEs of smaller sizes (0.01 μm in diameter) (Fig. 3 b–d). pvt-1 could be detected on some of the EEs, together with c-myc and IgH (not shown).
The colocalization of c-myc/IgH on some of the EEs raised the question of whether these EEs are biologically active structures. To investigate this hypothesis, we analyzed whether these EEs were associated with active chromatin, could transcribe c-myc mRNA, and confer c-Myc overexpression to resting primary B cells in extrachromosomal gene transfer studies.
To determine whether the EEs contained active genes, we (i) first examined the presence of histones and of the transcription-associated H3P (19, 22) on the EEs and (ii) then carried out mRNA track studies (Fig. 4 a and b). Using a pan-histone antibody that detects all histones irrespective of chromatin activation, we found histones on the large but not on the small EEs. To determine whether the former also were transcriptionally active, we examined the presence of H3P by using a monoclonal anti-histone H3P antibody (see Materials and Methods). We found that more than 90% of the pan-histone-containing EEs also stained with the monoclonal anti-histone H3P antibody, indicating that these EEs contained active chromatin (Fig. 4a).
To examine whether c-myc mRNA was produced from these EEs, we carried out mRNA track studies. As shown in Fig. 4b, we observed that multiple, short c-myc RNA tracks, typical of episomal (extrachromosomal) gene transcription (16), were generated from DCPC21-EEs. To unequivocally demonstrate that the mRNA was derived from the EEs, we processed the identical slides for FISH after RNase and pepsin treatment and after slide denaturation. Colocalizing c-myc mRNA (red signals) and c-myc-EEs DNA signals (green) are shown by arrows in Fig. 4c. We consistently observed that all c-myc mRNA tracks colocalized with EEs that showed c-myc DNA by FISH. However, the number of c-myc-carrying EEs in a DCPC21 cell was higher than the amount of EEs that were transcribing c-myc mRNA.
To further examine the functional activity of DCPC21 EEs, we electroporated purified EEs into normal BALB/cRb6.15 spleen cells together with a vector expressing GFP. The latter served as tracer molecule for gene transfer efficiency. The B lineage-specific marker B220 was used to determine the lineage origin of the electroporated cells. When purified DCPC21 EEs were introduced into normal BALB/cRb6.15 spleen cells, they conferred c-myc expression to GFP-expressing B220-positive B cells (Fig. 5A). However, within 24 hr, the DCPC-21 EEs induced cell death in the majority of the GFP-expressing B cells (>90%), whereas cells electroporated with GFP only survived. Cell death was associated with c-Myc overexpression and visible by the appearance of apoptotic bodies (Fig. 5B).
Discussion
c-myc/IgH-Carrying EEs Represent an Alternative Mechanism of c-Myc Overexpression in DCPC21 PCT.
In the present study, we have shown that DCPC21 PCT lacks any of the usual chromosomal translocations associated with c-myc gene deregulation in PCTs. Instead, we see the presence of c-myc and IgH together on EEs in this tumor. This raised the question of whether c-Myc deregulation in this PCT was linked to the presence of these EEs. Several experiments have confirmed that the c-myc/IgH-carrying EEs express c-Myc. We have directly shown c-myc mRNA tracks and active chromatin-associated histone H3 phosphorylation on these EEs. This was confirmed further by gene transfer experiments of the EEs. Transfer of EEs from DCPC21 cells into primary mouse B cells resulted in increased c-Myc expression followed by apoptotic cell death. We therefore conclude that the deregulated c-Myc expression in this PCT occurred by a mechanism not involving chromosomal translocation or viral insertion. This novel pathway of c-myc activation involves the formation of EEs that result in c-Myc expression levels similar to that seen in Ig/myc chromosomal translocation-positive PCTs.
Extrachromosomal DNA elements have been found in all organisms analyzed to date (for review see, ref. 23). EEs may be generated transiently during normal lymphocyte development (24, 25), but the size and numbers can vary depending on genotoxic treatments (26–28). Tumor cells often harbor EEs (29, 30), and these EEs can contain oncogenes and drug-resistance genes (31–37). In a previous study, the MOPC265 PCT cell line was shown to have a T(12;15) translocation that also contained c-myc and pvt-1 genes duplicated on chromosome 15 and on extrachromosomal elements (21). However, DCPC21 represents the first reported translocation-negative PCT carrying functional c-myc-transcribing EEs.
Model for the Generation of DCPC21-EEs Containing Both myc/pvt-1 and IgH Sequences.
The presence of c-myc/IgH-containing EEs raises the question about the mechanism(s) for their formation in the DCPC21 PCT. One possible model that is consistent with the experimental data is as follows. This model assumes independent generation of myc/pvt-1- and IgH-carrying EEs followed by recombination to generate myc/Ig-carrying EEs. Consistent with this model, we find EEs of various sizes, some of which carry both c-myc and IgH or either gene alone. A possible source for generation of these extrachromosomal elements could be Ig switch recombination, because circular elements containing Ig sequences have been described in normal B cell development (24). EEs that confer a growth/survival advantage, such as deregulated c-Myc expression, to the cell would be selected and maintained. Because we showed increased apoptotic cell death after gene transfer of EEs into normal B cells, other genetic events also would have to occur to prevent apoptosis during plasmacytomagenesis.
Are EEs Causally Involved in Other Translocation-Negative Tumors?
EEs are present in a variety of human tumors but their role in tumor initiation or progression is still poorly understood (38–40). The importance of amplified c-myc or N-myc genes, located on double-minute chromosomes (DMs), for maintenance of tumorigenicity has been shown. Elimination of the DMs results in reduced tumorigenicity (41–43).
Other human neoplasia that normally show specific translocations also have translocation-negative subsets. Recent analysis of a series of chronic myelogenous leukemia cells revealed an incongruity between the overexpression of the oncogenic BCR-ABL fusion protein and the absence of cytogenetically detectable T(9;22)(q34;q11) Philadelphia (Ph) chromosome (44–49). A recent investigation of the T(11;14) translocation and the overexpression of the MLL-AF4 fusion gene in acute lymphoblastic leukemia revealed that in 7 of 18 patients the generation of the MLL-AF4 protein occurred without detectable T(11;14) translocations (50). Burkitt lymphomas (BLs) usually contain Ig/myc-juxtaposed chromosomal translocations (for review, see refs. 51–53). We recently have found in a translocation-negative BL c-Myc overexpression from EEs containing c-myc and IgH sequences, without rearrangement of the chromosomal c-myc gene (unpublished data).
In conclusion, our results provide evidence that the EEs represent functional genetic units that may play an essential role transformation of the translocation-negative DCPC21 PCT. Our findings also suggest that other neoplasms with fusion transcripts or oncogene activation and amplification with no visible chromosomal translocations may indeed carry specific translocation(s) in an extrachromosomal form.
Acknowledgments
We thank Drs. M. Mowat and G. Hicks for critical reading of this manuscript and Margaret Skokan (Applied Spectral Imaging) for her help with SKY. This research was supported by a University of Manitoba Research Development Fund, the Medical Research Council, the Manitoba Cancer Treatment and Research Foundation, and CFI (Canada Foundation for Innovation).
Abbreviations
- PCT
plasmacytoma
- EE
extrachromosomal element
- FISH
fluorescent in situ hybridization
- SKY
spectral karyotyping
- H3P
phosphorylation of histone H3
- GFP
green fluorescent protein
- DAPI
4′,6-diamidino-2-phenylindole
Footnotes
This paper was submitted directly (Track II) to the PNAS office.
References
- 1.Cory S. Adv Cancer Res. 1986;47:189–234. doi: 10.1016/s0065-230x(08)60200-6. [DOI] [PubMed] [Google Scholar]
- 2.Ohno S, Babonits M, Wiener F, Spira J, Klein G, Potter M. Cell. 1979;18:1001–1007. doi: 10.1016/0092-8674(79)90212-5. [DOI] [PubMed] [Google Scholar]
- 3.Potter M, Wiener F. Carcinogenesis. 1992;13:1681–1697. doi: 10.1093/carcin/13.10.1681. [DOI] [PubMed] [Google Scholar]
- 4.Shaughnessy J D, Jr, Owens J D, Wiener F, Hilbert D M, Huppi K, Potter M, Mushinski J F. Oncogene. 1993;8:3111–3121. [PubMed] [Google Scholar]
- 5.Fahrlander P D, Sumegi J, Yang J, Wiener F, Marcu K B, Klein G. Proc Natl Acad Sci USA. 1984;81:7046–7050. doi: 10.1073/pnas.82.11.3746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ohno S, Migita S, Murakami S. Oncogene. 1989;4:1513–1517. [PubMed] [Google Scholar]
- 7.Ohno S, Migita S, Murakami S. Int J Cancer. 1991;49:102–108. doi: 10.1002/ijc.2910490119. [DOI] [PubMed] [Google Scholar]
- 8.Merwin R M, Redmon I W. J Natl Cancer Inst. 1963;31:998–1007. [PubMed] [Google Scholar]
- 9.Wang H C, Fedoroff S. Nature (London) 1971;235:52–54. doi: 10.1038/newbio235052a0. [DOI] [PubMed] [Google Scholar]
- 10.Committee on Standardized Genetic Nomenclature for Mice. Mouse News Letter. 1969;17:481–487. [Google Scholar]
- 11.Mai S, Hanley-Hyde J, Fluri M. Oncogene. 1996;12:277–288. [PubMed] [Google Scholar]
- 12.Fukasawa K, Wiener F, Vande Woude G F, Mai S. Oncogene. 1997;15:1295–1302. doi: 10.1038/sj.onc.1201482. [DOI] [PubMed] [Google Scholar]
- 13.Mai S. Gene. 1994;148:253–260. doi: 10.1016/0378-1119(94)90696-3. [DOI] [PubMed] [Google Scholar]
- 14.Greenberg R, Lang R B, Diamond M S, Marcu K B. Nucleic Acids Res. 1982;10:7751–7761. doi: 10.1093/nar/10.23.7751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Huppi K, Siwarski D, Skurla R, Klinman D, Mushinski J F. Proc Natl Acad Sci USA. 1990;87:6964–6968. doi: 10.1073/pnas.87.18.6964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Szeles A, Falk K I, Imreh S, Klein G. J Virol. 1999;73:5064–5069. doi: 10.1128/jvi.73.6.5064-5069.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lawrence J B, Singer R H, Marselle L M. Cell. 1989;57:493–502. doi: 10.1016/0092-8674(89)90924-0. [DOI] [PubMed] [Google Scholar]
- 18.Evan G I, Lewis G K, Ramsay G, Bishop J M. Mol Cell Biol. 1985;5:3610–3616. doi: 10.1128/mcb.5.12.3610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Juan G, Traganos F, James W M, Ray J M, Roberge M, Sauve D M, Anderson H, Darzynkiewicz Z. Cytometry. 1998;32:71–77. doi: 10.1002/(sici)1097-0320(19980601)32:2<71::aid-cyto1>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
- 20.Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Lab. Press; 1989. [Google Scholar]
- 21.Mai S, Hanley-Hyde J, Coleman A, Siwarski D, Huppi K. Genome. 1995;38:780–785. doi: 10.1139/g95-099. [DOI] [PubMed] [Google Scholar]
- 22.Juan G, Traganos F, Darzynkiewicz Z. Exp Cell Res. 1999;246:212–220. doi: 10.1006/excr.1998.4283. [DOI] [PubMed] [Google Scholar]
- 23.Gaubatz J W. Mutat Res. 1990;237:271–292. doi: 10.1016/0921-8734(90)90009-g. [DOI] [PubMed] [Google Scholar]
- 24.Iwasato T, Shimizu A, Honjo T, Yamagishi H. Cell. 1990;62:143–149. doi: 10.1016/0092-8674(90)90248-d. [DOI] [PubMed] [Google Scholar]
- 25.Matsuoka M, Yoshida K, Maeda T, Usuda S, Sakano H. Cell. 1990;6(2):35–142. doi: 10.1016/0092-8674(90)90247-c. [DOI] [PubMed] [Google Scholar]
- 26.Cohen S, Lavi S. Mol Cell Biol. 1996;16:2002–2014. doi: 10.1128/mcb.16.5.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Cohen S, Regev A, Lavi S. Oncogene. 1997;14:977–985. doi: 10.1038/sj.onc.1200917. [DOI] [PubMed] [Google Scholar]
- 28.Regev A, Cohen S, Cohen E, Bar-Am I, Lavi S. Oncogene. 1998;17:3455–3461. doi: 10.1038/sj.onc.1202250. [DOI] [PubMed] [Google Scholar]
- 29.Wahl G M. Cancer Res. 1989;49:1333–1340. [PubMed] [Google Scholar]
- 30.Cox D, Yuncken C, Spriggs A I. Lancet. 1965;2:55–58. doi: 10.1016/s0140-6736(65)90131-5. [DOI] [PubMed] [Google Scholar]
- 31.Fegan C D, White D, Sweeney M. Br J Haematol. 1995;90:486–488. doi: 10.1111/j.1365-2141.1995.tb05183.x. [DOI] [PubMed] [Google Scholar]
- 32.Wullich B, Muller H W, Fischer U, Zhang K D, Meese E. Eur J Cancer. 1993;29A:1991–1995. doi: 10.1016/0959-8049(93)90460-w. [DOI] [PubMed] [Google Scholar]
- 33.Chen T L, Manuelidis L. Genomics. 1989;4:430–433. doi: 10.1016/0888-7543(89)90351-0. [DOI] [PubMed] [Google Scholar]
- 34.Delinassios J G, Talieri M J. Experientia. 1983;39:1394–1395. doi: 10.1007/BF01990122. [DOI] [PubMed] [Google Scholar]
- 35.Rowland P, III, Pfeilsticker J, Hoffee P A. Arch Biochem Biophys. 1985;239:396–403. doi: 10.1016/0003-9861(85)90705-2. [DOI] [PubMed] [Google Scholar]
- 36.Wettergren Y, Kullberg A, Levan G. Hereditas. 1995;122:125–134. doi: 10.1111/j.1601-5223.1995.00125.x. [DOI] [PubMed] [Google Scholar]
- 37.Stahl F, Wettergren Y, Levan G. Mol Cell Biol. 1992;12:1179–1187. doi: 10.1128/mcb.12.3.1179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Trent J, Meltzer P, Rosenblum M, Harsh G, Kinzler K, Marshal R, Feinberg A, Vogelstein B. Proc Natl Acad Sci USA. 1986;83:470–473. doi: 10.1073/pnas.83.2.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Martinsson T, Stahl F, Pollwein P, Wenzel A, Levan A, Schwab M, Levan A. Oncogene. 1988;4:437–441. [PubMed] [Google Scholar]
- 40.Von Hoff D D, Needham-Van Devanter D R, Yucel Y, Windle B E, Wahl G M. Proc Natl Acad Sci USA. 1988;85:4804–4908. doi: 10.1073/pnas.85.13.4804. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Von Hoff D D, McGill J R, Forseth B J, Davidson K K, Bradley T P, Van Devanter D R, Wahl G M. Proc Natl Acad Sci USA. 1992;89:8165–8169. doi: 10.1073/pnas.89.17.8165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Eckhardt S G, Dai A, Davidson K K, Forseth B J, Wahl G M, Von Hoff D D. Proc Natl Acad Sci USA. 1994;91:6674–6678. doi: 10.1073/pnas.91.14.6674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Shimizu N, Nakamura H, Kadota T, Oda T, Hirano T, Utiyama H. Cancer Res. 1994;54:3561–3567. [PubMed] [Google Scholar]
- 44.van der Plas D C, Hermans A B, Soekarman D, Smit E M, de Klein A, Smadja N, Alimena G, Goudsmit R, Grosveld R, Hagemejer A. Blood. 1989;73:1038–1044. [PubMed] [Google Scholar]
- 45.Kurzrock R, Kantarjian H M, Shtalrid M, Gutterman J U, Talpaz M. Blood. 1990;75:445–452. [PubMed] [Google Scholar]
- 46.Costello R, Lafage M, Toiron Y, Brunel V, Sainty D, Arnoulet C, Mozziconacci M J, Bouabdallah R, Gastau J A, Maranichi D. Br J Hematol. 1995;90:346–352. doi: 10.1111/j.1365-2141.1995.tb05157.x. [DOI] [PubMed] [Google Scholar]
- 47.Selleri L, Milia G, Luppo M, Temperani P, Zucchini P, Tagliafico E, Astusi T, Sari M, Donelli A, Castoldi G L. Hematol Pathol. 1990;4:67–77. [PubMed] [Google Scholar]
- 48.Janssen J W, Fonatsch C, Ludwig W D, Bieder H, Maurer J, Bartram C R. Leukemia. 1992;6:463–464. [PubMed] [Google Scholar]
- 49.Estop A M, Sherer C, Cieply K, Groft D, Burcoglu A, Jhanwar S, Thomas J. Cancer Genet Cytogenet. 1997;96:174–176. doi: 10.1016/s0165-4608(96)00298-1. [DOI] [PubMed] [Google Scholar]
- 50.Uckun F M, Herman-Hatten K, Crotty M L, Sensel M G, Sather H N, Tuel-Ajlgren L, Sarquis M B, Bostrom B, Nachman J B, Steinherz P G, et al. Blood. 1998;92:810–821. [PubMed] [Google Scholar]
- 51.Klein G. Genes Chromosomes Cancer. 1989;1:3–8. doi: 10.1002/gcc.2870010103. [DOI] [PubMed] [Google Scholar]
- 52.Klein G. Gene. 1993;135:189–196. doi: 10.1016/0378-1119(93)90065-b. [DOI] [PubMed] [Google Scholar]
- 53.Klein G. Int J Dev Biol. 1995;39:715–718. [PubMed] [Google Scholar]